IMPORTANT NEWS ABOUT MONONINE®, COAGULATION FACTOR IX (HUMAN)
MONONINE will be discontinued in 2021. You will soon need to consider another treatment option.
At CSL Behring, we're committed to providing treatment and support services that make a meaningful difference in the lives of people with bleeding disorders. That's why we developed IDELVION®, Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rFIX-FP), a next-generation therapy indicated for: on-demand, prophylaxis, and perioperative treatment to manage bleeding episodes for hemophilia B.
WHEN SELECTING A NEW THERAPY, CHOOSE IDELVION
IDELVION OFFERS
Effective On-Demand Bleed Resolution
IDELVION resolves bleeds quickly, often in a single dose
Long-Lasting, Powerful Prophylactic Bleed Protection
In the IDELVION trial, adults and adolescents averaged 0 spontaneous and 0 joint bleeds per year when dosed every 7 or 14 days*
Individualized
Dosing Options
IDELVION has multiple dosing schedules, including 14-day prophylactic dosing, to meet varying needs†
Learn more about switching to IDELVION
- *Zero median annualized spontaneous and joint bleeding rate when dosed at 7 or 14 days in pivotal study.
- †Once well controlled (1 month without spontaneous bleeding or requiring dose adjustments on a weekly dose of ≤40 IU/kg), people 12 years and older can be transitioned to 14-day dosing.
- ‡Hemophilia FIX Market Assessment, Third-Party Market Research.